Journal of Nuclear Cardiology Philadelphia, PA - 19103

Journal of Nuclear Cardiology is categorized under Periodical Publishers in Philadelphia, PA .

Journal of Nuclear Cardiology was established in 0, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Periodical Publishers business, which does work in the B2B market, and is classified as a Periodical Publishers, under code number 5111200 by the NAICS.

If you are seeking more information, feel free to contact at the company’s single location by writing to 1600 John F Kennedy Boulevard # 1800, Philadelphia, Pennsylvania PA 19103 or by phoning (215) 239-3714. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Journal of Nuclear Cardiology
Address: 1600 John F Kennedy Boulevard # 1800, Philadelphia, Pennsylvania 19103
Phone Number: (215) 239-3714
Website Address: elsevier.com
Annual Revenue (USD): $2.500.000 to $4.999.999
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Periodical Publishers
SIC Code: 2721
NAICS Code: 5111200
Share This Business:

Journal of Nuclear Cardiology was started in 0 to provide professional Periodical Publishers under the SIC code 2721 and NAICS code 5111200. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.

Feel free to contact for inquiries that concern Journal of Nuclear Cardiology by calling the company number (215) 239-3714, as your correspondence is most welcome. Additionally, the physical location of the single location of Journal of Nuclear Cardiology can be found at the coordinates 39.953751,-75.166673 as well as the street address 1600 John F Kennedy Boulevard # 1800 in Philadelphia, Pennsylvania 19103.

For its online presence, you may visit Journal of Nuclear Cardiology’s website at elsevier.com and engage with its social media outlets through on Twitter and on Facebook.